en · de · es · fr · pt
selank-notes.peptides6908.com › Guide › Selank Origin And Chemical Identity — Deep Dive

Selank Origin And Chemical Identity — Deep Dive

By Editorial Desk · published 2025-07-21 · last reviewed 2025-08-04 · Guide

heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-08-04. Numbers and descriptions here follow the published literature rather than marketing material.

Selank Origin and Chemical Identity

Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.

Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.

Analytical Methods and Material Handling

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideAnalog of the tetrapeptide tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProReported consistently across pharmacopoeial descriptions
AppearanceWhite to off-white lyophilized powderTypical form of research-grade material
SolubilityFreely soluble in waterAqueous buffers; poor in nonpolar solvents
Typical storage temperature-20 degrees CelsiusLyophilized powder; protect from moisture

Mechanism and Evidence Base

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Related pages on this site

Identity and Structural Background

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Background and Peptide Identity

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Stability, Handling, and Analytical Control

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.

Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.

Supporting material

Significant 6d involvement is expected in the Nh–Au bond, although it is expected to be more unstable than the Tl–Au bond and entirely due to magnetic interactions. This raises the possibility of some transition metal character for nihonium. On the basis of the small energy gap between the 6d and 7s electrons, the higher oxidation states +3 and +5 have been suggested for nihonium. Some simple compounds with nihonium in the +3 oxidation state would be the trihydride (NhH3), trifluoride (NhF3), and trichloride (NhCl3). These molecules are predicted to be T-shaped and not trigonal planar as their boron analogues are: this is due to the influence of the 6d5/2 electrons on the bonding. The heavier nihonium tribromide (NhBr3) and triiodide (NhI3) are trigonal planar due to the increased steric repulsion between the peripheral atoms; accordingly, they do not show significant 6d involvement in their bonding, though the large 7s–7p energy gap means that they show reduced sp2 hybridisation compared to their boron analogues. The bonding in the lighter NhX3 molecules can be considered as that of a linear NhX+2 species (similar to HgF2 or AuF−2) with an additional Nh–X bond involving the 7p orbital of nihonium perpendicular to the other two ligands. These compounds are all expected to be highly unstable towards the loss of an X2 molecule and reduction to nihonium(I):

=== Cold War === The GIUK gap again became the focus of naval planning in the 1950s, as it represented the only available outlet into the Atlantic Ocean for Soviet submarines operating from their bases on the Kola Peninsula. NATO worried that if the Cold War "turned hot", naval convoys reinforcing Europe from the U.S. would suffer unacceptable losses if Soviet submarines could operate in the North Atlantic. The United States and the United Kingdom based much of their post-war naval strategy on blocking the gap, installing a chain of underwater listening posts right across it during the 1950s – an example of a SOSUS "sound surveillance system". This deployment of sonar surveillance in the gap, and elsewhere, hampered the Soviet Northern Fleet's ability to deploy its submarines without detection. The Royal Navy's primary mission during the Cold War, excluding its nuclear deterrent role, involved anti-submarine warfare (ASW). The development of the Invincible-class ASW aircraft carriers stemmed from this doctrine: their primary mission involved anti-submarine warfare using Sea King helicopters. The Type 23 frigate originated as a pure ASW platform; its mission expanded following the Falklands War of 1982. The largest Russian submarine drills through the GIUK gap were operations Aport and Atrina, in 1985 and 1987, respectively, when the Soviets deployed several nuclear-powered general-purpose attack submarines (SSNs) near the U.S. coast before the 1985 Gorbachev–Reagan meeting.

== Difference between channels and carriers == A carrier is not open simultaneously to both the extracellular and intracellular environments. Either its inner gate is closed, or its outer gate is closed. That is, its inner and outer gates are never open at the same time. In contrast, a channel can be open to both environments at the same time, allowing the molecules to diffuse without interruption. Carriers have binding sites, but pores and channels do not. When a channel is opened, millions of ions can pass through the membrane per second, but only 100 to 1000 molecules typically pass through a carrier molecule in the same time. Each carrier protein is designed to recognize only one substance or one group of very similar substances. Research has correlated defects in specific carrier proteins with specific diseases.

The overall fold of the KaiA monomer is that of a four-helix bundle, which forms a dimer in the known structure. KaiA functions as a homodimer. Each monomer is composed of three functional domains: the N-terminal amplitude-amplifier domain, the central period-adjuster domain and the C-terminal clock-oscillator domain. The N-terminal domain of KaiA, from cyanobacteria, acts as a pseudo-receiver domain, but lacks the conserved aspartyl residue required for phosphotransfer in response regulators. The C-terminal domain is responsible for dimer formation, binding to KaiC, enhancing KaiC phosphorylation and generating the circadian oscillations. The KaiA protein from Anabaena sp. (strain PCC 7120) lacks the N-terminal CheY-like domain. KaiB adopts an alpha-beta meander motif and is found to be a dimer or a tetramer. KaiC belongs to a larger family of proteins; it performs autophosphorylation and acts as its own transcriptional repressor. It binds ATP.

Sources: en.wikipedia.org

Notes from published material

The medical uses of silver include its use in wound dressings, creams, and as an antibiotic coating on medical devices. Wound dressings containing silver sulfadiazine or silver nanomaterials may be used to treat external infections. The limited evidence available shows that silver coatings on endotracheal breathing tubes may reduce the incidence of ventilator-associated pneumonia. There is tentative evidence that using silver-alloy indwelling catheters for short-term catheterizing will reduce the risk of catheter-acquired urinary tract infections. Silver generally has low toxicity, and minimal risk is expected when silver is used in approved medical applications. Alternative medicine products such as colloidal silver are controversial.

In reactor fuel, the fission product xenon, since it is almost insoluble in the lattice, tends to migrate to form bubbles in the fuel. As caesium 133, 135, and 137 are formed by the beta particle decay of the corresponding xenon isotopes, this causes the caesium to become physically separated from the bulk of the uranium oxide fuel. Because 135Xe is a potent nuclear poison with the largest cross section for thermal neutron absorption, the buildup of 135Xe in the fuel inside a power reactor can lower the reactivity greatly. If a power reactor is shut down or left running at a low power level, then large amounts of 135Xe can build up through decay of 135I. When the reactor is restarted or the low power level is increased significantly, 135Xe will be quickly consumed through neutron capture reactions and the reactivity of the core will increase. Under some circumstances, control systems may not be able to respond quickly enough to manage an abrupt reactivity increase as the built-up 135Xe burns off. It is thought that xenon poisoning was one of the factors which led to the power surge which damaged the Chernobyl reactor core.

Researchers report in a preprint the CRISPR alternative fanzor naturally present in eukaryotes with several potential advantages over CRISPR in genome editing, notably smaller size and higher selectiveness. A separate team further demonstrates in a preprint (14 June) the potential of this class of genome editors. 29 June – Astronomers report using a new technique to detect, for the first time, the release of neutrinos from the galactic plane of the Milky Way galaxy. Hazard research is published: study results suggest high-temperature cooking could cause DNA damage within food (especially meat) which in turn could cause human DNA damage (1 June), a study concludes the Italian Phlegraean Fields could be heading towards a first eruption since 1538 (9 June), a small team of researchers evaluates the credibility of net-zero climate targets as currently low (9 June), an AHA review shows that exposure to contaminant metals contributes to cardiovascular diseases (12 June), a study in the context of the opioid epidemic shows males are substantially (2–3 times greater) more vulnerable to or affected by drug overdose mortality than females (15 June), loss of Y chromosome can drive cancer growth (21 June), a study indicates nearly 40% of U.S.

==== Cationic head groups ==== Cationic surfactants are extensively described in this review. pH-dependent primary, secondary, or tertiary amines; primary and secondary amines become positively charged at pH < 10: octenidine dihydrochloride. Permanently charged quaternary ammonium salts: cetrimonium bromide (CTAB), cetylpyridinium chloride (CPC), benzalkonium chloride (BAC), benzethonium chloride (BZT), dimethyldioctadecylammonium chloride, and dioctadecyldimethylammonium bromide (DODAB).

The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of ketamine and related drugs like psychedelics for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult experiences and adverse effects, among others.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.

How does it relate to tuftsin?

The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.

Is Selank an approved medicine?

It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.

How is purity determined?

Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.

Network